Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
Top Cited Papers
- 1 March 2002
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 359 (9311), 1004-1010
- https://doi.org/10.1016/s0140-6736(02)08090-x
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Global and societal implications of the diabetes epidemicNature, 2001
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patientsJournal Of Hypertension, 2000
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic HypertensionNew England Journal of Medicine, 1999
- Characteristics of 9194 Patients With Left Ventricular HypertrophyHypertension, 1998
- Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDMDiabetes Care, 1998
- The Effect of Nisoldipine as Compared with Enalapril on Cardiovascular Outcomes in Patients with Non-Insulin-Dependent Diabetes and HypertensionNew England Journal of Medicine, 1998
- Diabetes and cardiovascular risk factors: the Framingham study.Circulation, 1979